Research programme: sapphyrin-derived apoptosis inducers - PharmacyclicsAlternative Names: PCI-2000; PCI-2022; PCI-2050; PCI-2051; PCI-2052; PCI-2053
Latest Information Update: 16 Oct 2009
At a glance
- Originator Pharmacyclics
- Class Porphyrins
- Mechanism of Action Apoptosis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Oct 2004 Data presented at the 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2004) have been added to the Cancer pharmacodynamics section
- 20 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the pharmacokinetics and Cancer pharmacodynamics sections
- 17 Dec 2003 Preclinical trials in Cancer in USA (IV)